Side-by-side · Research reference

SemaxvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft12/39 cited

BFDA-ApprovedVerified14/45 cited

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Semax

Tirzepatide

Primary target

BDNF / NGF expression + monoamine modulationKaplan 2017

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Semax

Tirzepatide

Standard dose

200–600 mcg / dose intranasalKaplan 2017

—

Frequency

2–3× per day during cognitive demand

—

Lower / starter dose

100 mcg / dose

—

Evidence basis

Human-mechanistic + Russian clinicalKaplan 2017

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

10–14 day cycles, repeated PRN

Indefinite for chronic indication

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

Morning + early afternoon

Once weekly, any time of day

Half-life

Short plasma; CNS effect lasts ~3–6 hr

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

Semax

Tirzepatide

Nasal irritation

Mild burning or congestion (transient)

—

Sleep disruption

Late-day dosing may interfere with sleep

—

Headache

Uncommon, transient

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

Contraindicated

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Semax

·Pregnancy / breastfeeding

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Semax

·Active psychiatric instability
·Concurrent strong stimulants

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Semax

Tirzepatide

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Administration

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Morning + early afternoon. Avoid evening (sleep disruption).

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Refrigerate after reconstitution; light-protected.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Caveat

Cycle on/off to avoid neurochemical adaptation.

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014

Tirzepatide

— no documented stacks